Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 07:00 source : Www.inventivapharma.com save search
Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023
Published: 2023-01-26 (Crawled : 07:00) - inventivapharma.com
IVA | $3.28 1.86% 6.7K
|
Health Technology
| Email alert
Add to watchlist
meeting results
Inventiva provides an update on the development of cedirogant by AbbVie
Published: 2022-10-31 (Crawled : 07:00) - inventivapharma.com
IVA | $3.28 1.86% 6.7K
|
Health Technology
|
| O: -15.24%
H: 0.0%
C: -7.47%
update
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
Published: 2022-03-08 (Crawled : 07:00) - inventivapharma.com
IVA | $3.28 1.86% 6.7K
|
Health Technology
|
| O: -0.18%
H: 2.55%
C: 1.91%
fda application ces trial nash
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.